New antibody combo shows promise against tough breast cancer
Disease control
Ongoing
This study tests a new drug called nadunolimab, given together with standard chemotherapy, for people with advanced triple-negative breast cancer (TNBC). TNBC is an aggressive type of breast cancer that is hard to treat. The goal is to see if adding nadunolimab can shrink tumors …
Phase: PHASE1, PHASE2 • Sponsor: Cantargia AB • Aim: Disease control
Last updated May 01, 2026 16:01 UTC